Granite Investment Partners LLC Buys Shares of 72,653 Aratana Therapeutics Inc (NASDAQ:PETX)

Granite Investment Partners LLC acquired a new stake in Aratana Therapeutics Inc (NASDAQ:PETX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 72,653 shares of the biopharmaceutical company’s stock, valued at approximately $382,000. Granite Investment Partners LLC owned approximately 0.17% of Aratana Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in shares of Aratana Therapeutics by 16.4% in the second quarter. Rhumbline Advisers now owns 48,214 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 6,800 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Aratana Therapeutics by 8.9% in the second quarter. Bank of New York Mellon Corp now owns 137,102 shares of the biopharmaceutical company’s stock worth $992,000 after purchasing an additional 11,229 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Aratana Therapeutics by 10.1% in the second quarter. Wells Fargo & Company MN now owns 303,988 shares of the biopharmaceutical company’s stock worth $2,197,000 after purchasing an additional 27,836 shares in the last quarter. Alliancebernstein L.P. grew its stake in Aratana Therapeutics by 26.1% during the second quarter. Alliancebernstein L.P. now owns 49,350 shares of the biopharmaceutical company’s stock valued at $357,000 after acquiring an additional 10,200 shares in the last quarter. Finally, Teachers Advisors LLC grew its stake in Aratana Therapeutics by 34.5% during the second quarter. Teachers Advisors LLC now owns 72,244 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 18,526 shares in the last quarter. 73.10% of the stock is currently owned by institutional investors.

In other Aratana Therapeutics news, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.70, for a total transaction of $5,075,941.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Peter Steven St sold 19,367 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total transaction of $92,380.59. Following the transaction, the chief executive officer now owns 672,259 shares in the company, valued at approximately $3,206,675.43. The disclosure for this sale can be found here. Insiders sold a total of 1,056,399 shares of company stock worth $6,087,271 over the last ninety days. Insiders own 5.20% of the company’s stock.

Shares of Aratana Therapeutics Inc (NASDAQ PETX) opened at $4.18 on Monday. The firm has a market cap of $179.74, a PE ratio of -2.88 and a beta of 3.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. Aratana Therapeutics Inc has a 1 year low of $3.91 and a 1 year high of $7.67.

Several equities analysts recently commented on PETX shares. HC Wainwright started coverage on shares of Aratana Therapeutics in a research note on Friday, November 17th. They set a “buy” rating and a $10.00 price objective for the company. Jefferies Group set a $9.00 price objective on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 16th. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Thursday, November 9th. Stifel Nicolaus restated a “hold” rating and issued a $6.00 price objective on shares of Aratana Therapeutics in a report on Monday, December 18th. Finally, CL King assumed coverage on shares of Aratana Therapeutics in a report on Wednesday, December 27th. They set a “neutral” rating for the company. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $8.55.

ILLEGAL ACTIVITY NOTICE: “Granite Investment Partners LLC Buys Shares of 72,653 Aratana Therapeutics Inc (NASDAQ:PETX)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/19/granite-investment-partners-llc-buys-new-holdings-in-aratana-therapeutics-inc-petx.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply